ChemInform Abstract: An Overview of Cyclophosphamide Development and Clinical Applications

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Clinical trial: cyclophosphamide pulse therapy – a promising therapeutic alternative in refractory Crohn’s disease

“…Duration of response after cyclophosphamide in these patients lasted a median 10 months (range [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. In this group, three patients had achieved remission and one patient had experienced a response to the cyclophosphamide pulse therapy.…”

“…Cyclophosphamide is mainstay in the treatment of systemic vasculitis such as systemic lupus erythematodes, vasculitic forms of rheumatoid arthritis or Wegener's granulomatosis, diseases that share pathogenic features with IBD. [9][10][11] Recent data demonstrated efficacy of cyclophosphamide in the Vogt-Koyanagi-Harada Syndrome. 12 This granulomatous uveitis is critically driven by the IL17 ⁄ 23 pathway, a characteristic feature of CD.…”

Effect of cyclophosphamide on the microanatomy of liver of albino rats

“…It was first synthesized in 1958 by Arnold and Bourseaux 1 and was approved for use in United States in 1959. It is given orally as well as parenterally.…”

Protective effect of simvastatin in the cyclophosphamide-induced hemohrragic cystitis in rats

“…It is metabolized in the liver to its active form and eliminated primarily via renal excretion. A small portion of the cyclophosphamide is converted to a metabolite, acrolein, the causative agent responsible for CYP induced hemohrragic cystitis (HC) 8 . Histologically, acrolein imparts a great inflammatory response characterized by subepithelial edema, neutrophil infiltration, hemorrhage and necrosis.…”